Close Menu

NEW YORK — Centogene said on Monday that it has signed an agreement to provide diagnostic testing services for aromatic L-amino acid decarboxylase (AADC) deficiency to PTC Therapeutics, which is developing a treatment for the rare disease.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.